Medtronic (NYSE:MDT) reported first quarter fiscal 2027 revenue of $9.756 billion, up 13.7% year over year on both reported and organic bases, including an estimated $570 million benefit from an additional fiscal week.
Medtronic (NYSE:MDT) reported a 9.9% increase in fourth-quarter revenue to $9.8 billion, closing out its fiscal year 2026 with broad-based operational momentum across its core therapeutic portfolios.
Medtronic (NYSE:MDT) reported third-quarter fiscal 2026 revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis, surpassing the midpoint of its guidance by 50 basis points and marking the highest enterprise revenue growth in the past 10 quarters.
Medtronic (NYSE:MDT) announced a definitive agreement to acquire SPR Therapeutics, a privately held medical technology company specializing in temporary peripheral nerve stimulation (PNS) therapies for chronic pain management.
Medtronic (NYSE:MDT) announced a definitive agreement on Tuesday to acquire Scientia Vascular, a privately held medical technology firm specializing in high-performance access products for neurovascular procedures.
